azidoamphenicol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 62858 |
| CHEMBL ID | 3989525 |
| CHEBI ID | 135238 |
| MeSH ID | M0045505 |
| Synonym |
|---|
| 13838-08-9 |
| azidamfenicol (inn/ban/dcf) |
| D07411 |
| posifenicol (tn) |
| azidamfenicol |
| CHEBI:135238 |
| 2-azido-n-[(1r,2r)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide |
| d(-)-threo-2-azido-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)acetamide |
| leukomycin n |
| azidanfenicol |
| azidamphenicolum |
| threo-2-azido-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)acetamide |
| azidamfenicolum |
| azidoamphenicol |
| bay f 4797 |
| acetamide, 2-azido-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, d-threo-(-)- |
| acetamide, 2-azido-n-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (r-(r*,r*))- |
| azidanfenicol [inn-spanish] |
| acetamide, 2-azido-n-((1r,2r)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)- |
| unii-40257685lm |
| azidamfenicolum [inn-latin] |
| thilocof |
| bayer 52910 |
| 40257685lm , |
| einecs 237-552-9 |
| thilocanfol |
| azidamfenicol [inn:ban:dcf] |
| azidamphenicol |
| berlicetin |
| posifenicol |
| azidoamfenicol |
| azidamfenicol [mart.] |
| azidamfenicol [mi] |
| azidamfenicol [inn] |
| d(-)-threo-2-azido-n-(.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl)acetamide |
| azidamfenicol [who-dd] |
| DTXSID90160647 |
| J-007130 |
| Q425029 |
| DB13294 |
| CHEMBL3989525 |
| HY-105674 |
| CS-0026430 |
| gtpl12397 |
| AKOS040741205 |
| Class | Description |
|---|---|
| organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
| organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 2 (40.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||